These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28683461)

  • 21. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
    Freeman L; Kee A; Tian M; Mehta R
    Drugs Real World Outcomes; 2021 Dec; 8(4):497-508. PubMed ID: 34136997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does a multimethod approach improve identification of medication nonadherence in adolescents with chronic kidney disease?
    Pruette CS; Coburn SS; Eaton CK; Brady TM; Tuchman S; Mendley S; Fivush BA; Eakin MN; Riekert KA
    Pediatr Nephrol; 2019 Jan; 34(1):97-105. PubMed ID: 30116892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis.
    Thach AV; Brown CM; Herrera V; Sasane R; Barner JC; Ford KC; Lawson KA
    Int J MS Care; 2018; 20(6):251-259. PubMed ID: 30568562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
    Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantifying Glaucoma Medication Adherence: The Relationship Between Self-Report, Electronic Monitoring, and Pharmacy Refill.
    Kumar JB; Bosworth HB; Sleath B; Woolson S; Olsen M; Danus S; Muir KW
    J Ocul Pharmacol Ther; 2016; 32(6):346-54. PubMed ID: 27058842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis.
    Schwartz CE; Grover SA; Powell VE; Noguera A; Mah JK; Mar S; Mednick L; Banwell BL; Alper G; Rensel M; Gorman M; Waldman A; Schreiner T; Waubant E; Yeh EA
    Mult Scler; 2018 Feb; 24(2):175-185. PubMed ID: 28273780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
    Gaindh D; Kavak KS; Teter B; Vaughn CB; Cookfair D; Hahn T; Weinstock-Guttman B;
    J Neurol Sci; 2016 Nov; 370():13-17. PubMed ID: 27772741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
    Hansen K; Schüssel K; Kieble M; Werning J; Schulz M; Friis R; Pöhlau D; Schmitz N; Kugler J
    PLoS One; 2015; 10(7):e0133279. PubMed ID: 26214805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of pharmacy dispensing records in the evaluation of adherence to antiretroviral therapy in Brazilian children and adolescents.
    Ernesto AS; Lemos RM; Huehara MI; Morcillo AM; Dos Santos Vilela MM; Silva MT
    Braz J Infect Dis; 2012; 16(4):315-20. PubMed ID: 22846117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring the Agreement Between Self-Reported Medication Adherence and Pharmacy Refill-Based Measures in Patients with Kidney Disease.
    Murali KM; Mullan J; Roodenrys S; Cheikh Hassan HI; Lonergan MA
    Patient Prefer Adherence; 2022; 16():3465-3477. PubMed ID: 36605331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with adherence to disease modifying therapy in multiple sclerosis: An observational survey from a referral center in Lithuania.
    Duchovskiene N; Mickeviciene D; Jurkeviciene G; Dirziuviene B; Balnyte R
    Mult Scler Relat Disord; 2017 Apr; 13():107-111. PubMed ID: 28427690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationships between multiple self-reported nonadherence measures and pharmacy records.
    Rickles NM; Svarstad BL
    Res Social Adm Pharm; 2007 Dec; 3(4):363-77. PubMed ID: 18082873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk Factors for Suboptimal Medication Adherence in Persons With Multiple Sclerosis: Development of an Electronic Health Record-Based Explanatory Model for Disease-Modifying Therapy Use.
    Gromisch ES; Turner AP; Leipertz SL; Beauvais J; Haselkorn JK
    Arch Phys Med Rehabil; 2020 May; 101(5):807-814. PubMed ID: 31809751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of methods to assess medication adherence and classify nonadherence.
    Hansen RA; Kim MM; Song L; Tu W; Wu J; Murray MD
    Ann Pharmacother; 2009 Mar; 43(3):413-22. PubMed ID: 19261962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.
    Halpern R; Agarwal S; Borton L; Oneacre K; Lopez-Bresnahan MV
    Adv Ther; 2011 Sep; 28(9):761-75. PubMed ID: 21870169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy.
    Marangi A; Farina G; Vicenzi V; Forlivesi S; Calabria F; Marchioretto F; Forgione A; Rossi F; Stenta G; Vianello M; Gajofatto A; Benedetti MD
    Mult Scler Relat Disord; 2020 Jun; 41():102004. PubMed ID: 32078935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: Real world evidence from Alberta, Canada.
    Gerber B; Cowling T; Chen G; Yeung M; Duquette P; Haddad P
    Mult Scler Relat Disord; 2017 Nov; 18():218-224. PubMed ID: 29141814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of COVID-19 and system recovery in delivering healthcare to people with multiple sclerosis: a population-based Study.
    Affinito G; Trama U; Palumbo L; Fumo MG; Giordana R; Di Gennaro M; Triassi M; Lanzillo R; Morra VB; Palladino R; Moccia M
    Neurol Sci; 2023 Nov; 44(11):3771-3779. PubMed ID: 37672178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosis.
    Brandes DW; Raimundo K; Agashivala N; Kim E
    J Med Econ; 2013; 16(4):547-51. PubMed ID: 23391123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.